Sutro Biopharma, Inc. Forecast, price target & analysts
Sutro Biopharma, Inc. Target price 2026 - Analyst rating & recommendation
Sutro Biopharma, Inc. Classifications & Recommendation
Sutro Biopharma, Inc. Price Target
| Target Price | $51.00 |
| Price | $15.35 |
| Potential |
232.25%
register free of charge
|
| Number of Estimates | 15 |
|
15 Analysts have issued a price target Sutro Biopharma, Inc. 2027 .
The average Sutro Biopharma, Inc. target price is $51.00.
This is
232.25%
register free of charge
$64.05
317.26%
register free of charge
$10.10
34.20%
register free of charge
|
|
| A rating was issued by 20 analysts: 18 Analysts recommend Sutro Biopharma, Inc. to buy, 1 to hold and 1 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Sutro Biopharma, Inc. stock has an average upside potential 2027 of
232.25%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million $ | 102.48 | 45.75 |
| 65.18% | 55.35% | |
| EBITDA Margin | -95.27% | -234.85% |
| 74.44% | 146.52% | |
| Net Margin | -186.47% | -317.35% |
| 49.14% | 70.19% |
15 Analysts have issued a sales forecast Sutro Biopharma, Inc. 2026 . The average Sutro Biopharma, Inc. sales estimate is
This results in the following potential growth metrics:
5 Analysts have issued an Sutro Biopharma, Inc. EBITDA forecast 2026. The average Sutro Biopharma, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
16 Sutro Biopharma, Inc. Analysts have issued a net profit forecast 2026. The average Sutro Biopharma, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -22.49 | -8.76 |
| 24.05% | 61.05% | |
| P/E | negative | |
| EV/Sales | 7.20 |
16 Analysts have issued a Sutro Biopharma, Inc. forecast for earnings per share. The average Sutro Biopharma, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Sutro Biopharma, Inc....
Current Sutro Biopharma, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Wedbush |
Locked
➜
Locked
|
Locked | Aug 13 2026 |
| Citizens |
Locked
➜
Locked
|
Locked | Aug 13 2026 |
| Barclays |
Locked
➜
Locked
|
Locked | May 28 2026 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | May 15 2026 |
| Leerink Partners |
Locked
➜
Locked
|
Locked | May 15 2026 |
| Wedbush |
Locked
➜
Locked
|
Locked | May 15 2026 |
| Mizuho |
Locked
➜
Locked
|
Locked | Apr 30 2026 |
| Analyst Rating | Date |
|---|---|
|
Locked
Wedbush:
Locked
➜
Locked
|
Aug 13 2026 |
|
Locked
Citizens:
Locked
➜
Locked
|
Aug 13 2026 |
|
Locked
Barclays:
Locked
➜
Locked
|
May 28 2026 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
May 15 2026 |
|
Locked
Leerink Partners:
Locked
➜
Locked
|
May 15 2026 |
|
Locked
Wedbush:
Locked
➜
Locked
|
May 15 2026 |
|
Locked
Mizuho:
Locked
➜
Locked
|
Apr 30 2026 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
